The authorised ANDA, Nystatin and Triamcinolone Acetonide Ointment is used to treat cutaneous candidiasis; studies have indicated that the nystatin-steroid combination is more effective in the first few days of therapy than the nystatin component alone.
Alembic Pharmaceuticals Limited confirmed that its joint venture Aleor Dermaceuticals Limited has gained the final FDA clearance for its Abbreviated New Drug Application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. The authorised ANDA, Nystatin and Triamcinolone Acetonide Ointment is used to treat cutaneous candidiasis; studies have indicated that the nystatin-steroid combination is more effective in the first few days of therapy than the nystatin component alone.